You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 56 No. 4, April 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  News and Views
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (6)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal

Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion

William E. Bunney, Jr, MD; Daniel L. Azarnoff, MD; Byron W. Brown, Jr, PhD; Robert Cancro, MD; Robert D. Gibbons, PhD; John C. Gillin, MD; Sandral Hullett, MD, PhD; Keith F. Killam, PhD; David J. Kupfer, MD; John H. Krystal, MD; Paul D. Stolley, MD, MPH; Geoffrey S. French, MA; Andrew M. Pope, PhD

Arch Gen Psychiatry. 1999;56:349-352.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Recent estimates indicate that there is a 10% prevalence of chronic insomnia in the adult population of the United States, with an associated annual cost of $90 to $107 billion.1 Since its approval in 1982 for use in the treatment of insomnia, an estimated 11 billion prescriptions for Halcion (triazolam) have been filled worldwide.2 Halcion refers to the actual product that is manufactured and marketed by the Upjohn Co (hereinafter, Upjohn), Kalamazoo, Mich. Triazolam is the generic name of the pure active ingredient in Halcion. The committee uses the term Halcion in the text when it . . . [Full Text of this Article]

ASSESSMENT OF EFFICACY DATA

DATA ADEQUACY

Recommendation 1.

CLINICAL TRIAL DESIGN

Recommendation 2.

Recommendation 3.

TOLERANCE

Recommendation 4.

ASSESSMENT OF SAFETY DATA

CLINICAL TRIALS AND SURVEILLANCE

Recommendation 5.

BROADER IMPLICATIONS

Recommendation 6.

Recommendation 7.

Drs Bunney (chair), Azarnoff, Brown, Cancro, Gibbons, Gillin, Hullett, Killam, Kupfer, Krystal, and Stolley are members of the Institute of Medicine Committee on the Efficacy and Safety of Halcion; Mr French and Dr Pope are staff members of the Institute of Medicine, Washington, DC. Dr Killam is deceased.


RELATED ARTICLES

The Report by the Institute of Medicine and Postmarketing Surveillance
Donald F. Klein
Arch Gen Psychiatry. 1999;56(4):353-354.
EXTRACT | FULL TEXT  

Long-term Use of Sedative and Hypnotic Medication
David L. Dunner
Arch Gen Psychiatry. 1999;56(4):355.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Bum Rap for Triazolam
JWatch Psychiatry 1999;1999:2-2.
FULL TEXT  

The Report by the Institute of Medicine and Postmarketing Surveillance
Klein
Arch Gen Psychiatry 1999;56:353-354.
FULL TEXT  

Long-term Use of Sedative and Hypnotic Medication
Dunner
Arch Gen Psychiatry 1999;56:355-355.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.